Facial Nerve Palsy as a Common Presentation during the Epidemic of Coronavirus Disease Associated Rhinocerebral Mucormycosis

Y. Mounika Reddy1 · Nitya Goddanti1 · Kiran Kumar1 · Aparna Suresh1 · Rajesh Muderla1 · T. Shankar1 · Manish Gupta1 · K. Sreenivas3 · Subramanyam Darbha3

Received: 12 August 2021 / Accepted: 19 August 2022 / Published online: 4 September 2022
© Association of Otolaryngologists of India 2022

Abstract

Purpose The main purpose of this study is to highlight the involvement of the facial nerve as one of the presenting symptoms in patients suspected of coronavirus disease associated mucormycosis (CAM).

Methods This is a retrospective observational study conducted at a tertiary care referral centre which included 300 patients with past history of being treated for coronavirus disease and who presented to our department with symptoms of invasive fungal sinusitis. All the patients were evaluated clinically and radiologically for presence of facial nerve palsy (FNP) in suspected cases of CAM. All the patients were managed with combined modality treatment with antifungal therapy and radical endoscopic debridement of the necrotic tissue and fungal debris.

Results The data were analysed to assess the possible epidemiological factors linked to CAM. Diabetes mellitus was the most common associated factor identified for aggravating of CAM. FNP is also one of the common presentation seen among 53 patients with CAM.

Conclusion FNP is an unusual but significant sign in presentation of mucormycosis. It could be easily misdiagnosed as cerebrovascular accident leading to delay in the treatment. During this era of Covid-19 pandemic where wearing of masks has become mandatory, there is a high probability of this finding to be missed. Thus, our study emphasises for thorough cranial nerve examination in all cases of CAM, for an early and an immediate intervention to prevent the spread of the disease and also to improve the overall general condition of the patient.

Keyword Coronavirus · Mucormycosis · Invasive fungal sinusitis · Facial nerve palsy · Greater superficial petrosal nerve

Introduction

The global Coronavirus disease 2019 (Covid-19) pandemic has affected more than 30 million people in India till date and several have succumbed to the disease. As India continues to fight and gain stability over the existing scenario, another imminent threat has emerged as a challenge to India in the form of coronavirus disease associated mucormycosis (CAM). Covid-19 is an infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which principally binds to the angiotensin converting enzyme 2 receptors and thus invades the respiratory epithelium. The second stage of this disease is more severe caused by aggravation of systemic inflammation and coagulopathy causing direct endothelial damage to the blood vessels and microvascular thrombus formation. Moreover, affected patients likewise show an overexpression of inflammatory cytokines, and impaired cell mediated immunity thus leading to increased susceptibility to fungal infections.

Mucormycosis (the so called black fungus) is a rare, angioinvasive infection that typically affects immunocompromised individuals. Depending on the site affected it can manifest as one of seven different clinical syndromes such as rhino-orbito cerebral, pulmonary, gastrointestinal, central nervous system, cutaneous, disseminated, miscellaneous
(bones, joints, heart, kidney, mediastinum). Rhino-orbito-cerebral type is the commonest type accounting for about 30–50% of the cases and also rapidly progresses through the stages of rhinomaxillary, rhino-orbital and rhino-orbito-cerebral mucormycosis (ROCM). In the past 3 months, we have seen an immense increase in the numbers of cases of CAM at our nodal centre. The high incidence of diabetes in our Indian population alongside with excessive use of corticosteroids as a part of treatment for Covid-19 could also be a probability for increased numbers. Coagulopathy leading to several peripheral microthrombi, microangiopathy from diabetes mellitus in addition to immunosuppression from corticosteroids all could have been a cause in providing an ideal host for the fungus to grow. Typical presentation of ROCM includes nasal stuffiness, headache, facial pain, retro-orbital pain, orbital swelling, ophthalmoplegia and visual loss. Involvement of the cranial nerves although not very common, facial nerve palsy (FNP) is a rare finding which has been documented previously. The purpose of this article is to make ENT surgeons aware of this uncommon presentation of ROCM. Timely diagnosis and early recognition of the signs and symptoms, correction of underlying medical disorders, and aggressive medical treatment with antifungal and surgical intervention are necessary for successful therapeutic outcome.

**Materials and Methods**

This is a retrospective observational study which was conducted at our tertiary care nodal centre in India for the treatment of CAM between April 2021 and June 2021 after obtaining an institute ethical committee approval. This study included 300 patients with past history of recently being treated for Covid-19 infection and who presented to our department with symptoms and signs of ROCM. Patients were characterized as recovered from Covid-19 if they were tested negative on a repeat RT-PCR (reverse transcriptase polymerase chain reaction) or if fourteen days had elapsed since the diagnosis.

Patients were also assessed for the following history before deciding the treatment protocol 1. History of Covid-19 infection 2. Diabetes status of the patient (pre-existing or newly diagnosed) 3. History of steroid use during Covid-19 infection.

Patients with a history of radiotherapy, chemotherapy, osteoradionecrosis of the jaw, granulocytopenic patients or those on other immunomodulator drugs were excluded from the study. Patients with non Covid-19 associated ROCM were also excluded from the study.

The patients who presented with one or more of the following symptoms and signs of headache, facial pain, jaw pain or necrosis of the mucosa or the palatal bone, retro-orbital pain, swelling of the eye or proptosis, ptosis and visual disturbances (Fig. 1) suspicious of ROCM were all included in the study.

**Intervention**

All patients underwent thorough ENT and cranial nerve examination. Patient were checked for swelling of the eye (proptosis), drooping of the upper eyelid (ptosis), loss of vision or visual disturbances, and facial nerve involvement with signs of drooping of the corner of the mouth, drooling of saliva and absence of wrinkles in half of the forehead (suggestive of lower motor neuron palsy). Aside from ascertaining the current Covid-19 status with RT-PCR test, routine blood investigations and high resolution computed tomography of the chest were done for all the patients. Diagnostic nasal endoscopy was performed to look for necrotic tissue, black eschar or fungal debris i.e., signs of invasive fungal sinusitis (Fig. 1). Magnetic resonance imaging (MRI) of the paranasal sinuses (PNS) including orbits and brain were performed for all cases (Fig. 2). Patients were taken up for surgical exploration and debridement, under endoscopic guidance and the infected tissue was sent for microbiological and histopathological examination (HPE) to determine and confirm the presence of fungal hyphae (Fig. 1). The surgical intervention varied from a simple surgical debridement to maxillectomy (partial/subtotal/total) to orbital exenteration depending on the extent of disease. Depending on the type of fungal organism, liposomal amphotericin therapy was instituted at 5 mg/kg for mucormycosis. Later at the time of discharge patients were started on oral posaconazole 300 mg every 8th hourly on the first day and then continued at once daily dosage. Due to high possibility of nephrotoxicity and electrolyte disturbances due to liposomal amphotericin B, daily renal function tests and serum electrolytes were performed, monitored and managed appropriately. The patients were followed up after discharge regularly at weekly intervals and were taken up for further surgical debridement if any suspicious lesions were noted.

**Measurement**

Patients were assessed for the presence of facial nerve palsy in ROCM, whether it was lower motor neurone type or upper motor neurone type. Radiologically the various sites of involvement of sinuses due to the spread of mucormycosis has also been studied.

**Statistical Methods**

Statistical analysis was performed by a department appointed statistician. The data of the patients demographic details, co-morbidities, history in regards to management with use
of corticosteriods, Covid-19 infection, symptomatology and involvement of facial nerve were all collected, obtained and analysed. Descriptive statistics for patient characteristics included the mean, standard deviation, median and range for continuous variables, and frequencies and percentages for categorical items. Statistical analysis software STATA (StataCorp LLC, 4905 Lakeway Drive College Station, Texas) v.11.2 was used for data analysis.

Results

Among the 300 patients who were included in the study, 227 (75.6%) were males and 73 (24.33%) were females, with ratio between males to females to be 3.1:1. The age of the patients ranged from 18 to 80 years with a mean age of 47.05 ± 10.7 years.

Out of the 300 patients suspected CAM the most common epidemiological factor was diabetes mellitus. Majority 285 (95%) patients were either newly diagnosed 152 (50.67%) or pre-existing diabetics 133 (44.33%) and 253 (84.33%) received corticosteriods during management of Covid-19 infection.

Table 1 summarises the symptoms of CAM among 300 patients who were included in the study. FNP was seen among 53 (17.67%) out of 300 patients included in the study. Table 2 summarises distribution of signs of ptosis, loss of vision among patients with FNP. 45 out of 300 patients had ptosis, vision loss and facial nerve palsy. Table 3 summarises the involvement of various sinuses, premaxillary area, retromaxillary area, orbit, orbital apex, optic nerve, and cavernous sinus.

All patients underwent preoperative DNE, imaging, followed by immediate surgical management and the excised...
tissue was sent for HPE. HPE confirmed mucormycosis was seen in 262 (87.33%) patients, aspergillosis in 11 patients, mixed infection in 4 patients and rest others showed features of chronic sinusitis.

Table 4 summarises the association of FNP with DM and Mucormycosis. 52 out of the total 53 patients with FNP were diabetics.

Discussion

Mucormycosis is a rare, opportunistic, fulminant, angioinvasive fungal infection caused by rhizopus species of the order mucorales and was first described by Paul tauf in 1885 [1]. It mainly affects immunocompromised individuals, predisposed by diabetes mellitus, corticosteroids, immunosuppressive therapy, haematological malignancies and organ transplantation [2]. The fungi are ubiquitous and are seen mainly on plants and animal matter. In patients with diabetes, hyperglycaemia along with low pH acidic environment produces a favourable environment for the spores to germinate. The inhaled spores of the fungi get inoculated into the nose and nasopharynx, leading to tissue invasion, thrombosis, and necrosis. The fungal hyphae are highly angioinvasive and have a great affinity towards the internal elastic lumina of the arterial blood vessels thus ensuing thromboembolism and causing subsequent thrombotic infarction [3]. Most commonly seen is the thrombosis of the sphenopalatine artery or internal maxillary artery thus producing a characteristic black necrotic eschar on which the fungus thrives. This necrosis causes rapid spread of infection from the nose to the PNS, to the orbit, cavernous sinus and then to the intracranial cavity via angular, ethmoidal and lacrimal vessels. Intracranial spread can occur within days from the orbit via orbital vessels, or via cribiform plate [4].

Typical clinical presentation of ROCM includes headache, facial pain or swelling, retro-orbital pain and jaw pain. As the disease advances patients may present with ptosis, proptosis, loss of vision, palatal eschar with multiple cranial nerve palsy [5–7]. Ptosis could be due to direct involvement of retro-orbital tissues, levator palpable superiors muscle or the oculomotor nerve extending into the cavernous sinus. Loss of vision may result from direct involvement of the optic nerve or due to central retinal artery occlusion or endophthalmitis. Bilateral eye signs are suggestive of involvement of the cavernous sinus. The orbital findings in our study revealed ptosis, proptosis and vision disturbances. Retro-orbital pain or swelling was observed in 221 (73.67%) of patients by us compared with 43% by Yohai et al. [8]. Ptosis was reported in 96 (32%) of patients. In our study loss of vision
### Table 1: Distribution of symptoms and signs of ROCM among 300 patients of CAM

| Symptoms/signs                  | Male               | Female             | Total              |
|--------------------------------|--------------------|--------------------|--------------------|
| **Headache**                   |                    |                    |                    |
| Yes                            | 160/227 (70.48%)   | 48/73 (65.75%)     | 208/300 (69.33%)   |
| No                             | 67/227 (29.52%)    | 25/73 (34.25%)     | 92/300 (30.67%)    |
| **Eye pain**                   |                    |                    |                    |
| Yes                            | 170/227 (74.89%)   | 51/73 (69.86%)     | 221/300 (73.67%)   |
| No                             | 57/227 (25.11%)    | 22/73 (30.14%)     | 79/300 (26.33%)    |
| **Facial pain**                |                    |                    |                    |
| Yes                            | 193/227 (85.02%)   | 60/73 (82.19%)     | 253/300 (84.33%)   |
| No                             | 34/227 (14.98%)    | 13/73 (17.81%)     | 47/300 (15.67%)    |
| **Jaw pain/palatal eschar**    |                    |                    |                    |
| Present                        | 46/227 (20.26%)    | 10/73 (13.70%)     | 56/300 (18.67%)    |
| Absent                         | 181/227 (79.74%)   | 63/73 (86.30%)     | 244/300 (81.33%)   |
| **Loss of vision**             |                    |                    |                    |
| Present                        | 75/227 (33.04%)    | 25/73 (34.25%)     | 100/300 (33.33%)   |
| Absent                         | 152/227 (66.96%)   | 48/73 (65.75%)     | 200/300 (66.67%)   |
| **Ptosis**                     |                    |                    |                    |
| Present                        | 77/227 (33.92%)    | 19/73 (26.03%)     | 96/300 (32.00%)    |
| Absent                         | 150/227 (66.08%)   | 54/73 (73.97%)     | 204/300 (68.00%)   |
| **Facial nerve palsy**         |                    |                    |                    |
| Present                        | 42/227 (18.50)     | 11/73 (15.07)      | 53/300 (17.67)     |
| Absent                         | 185/227 (81.50)    | 62/73 (84.93)      | 247/300 (82.33)    |
| **Side of FNP**                |                    |                    |                    |
| Right                          | 31 (13.66%)        | 7 (9.59%)          | 38 (12.67%)        |
| Left                           | 11 (4.85%)         | 3 (4.11%)          | 14 (4.67%)         |
| None                           | 185 (81.50%)       | 63 (86.30%)        | 248 (82.67%)       |
| Present                        | 14 (6.17%)         | 3 (4.11%)          | 17 (5.67%)         |
| Absent                         | 213 (93.83%)       | 70 (95.89%)        | 283 (94.33%)       |
| **DNE—black eschar**           |                    |                    |                    |
| Present                        | 170/227 (74.89)    | 58/73 (79.45)      | 228/300 (76.00)    |
| Absent                         | 57/227 (25.11)     | 15/73 (20.55)      | 72/300 (24.00)     |
| **Mucormycosis HPE**           |                    |                    |                    |
| Yes                             | 200/227 (88.11%)   | 62/73 (84.93%)     | 262/300 (87.33%)   |
| No                              | 27/227 (11.89%)    | 11/73 (15.07%)     | 38/300 (12.67%)    |

### Table 2: Distribution of association between ptosis, loss of vision and facial nerve palsy among 300 patients of CAM

| Sign                          | Facial nerve palsy (FNP) |
|-------------------------------|-------------------------|
| Ptosis                        | FNP Present 53 (17.67%) | FNP Absent 247 (82.33%) |
| Present (96)                  | 51 (53.13%)             | 45 (46.88%)             |
| Absent (204)                  | 2 (0.98%)               | 202 (99.02%)            |
| Loss of Vision                | FNP Present 53 (17.67%) | FNP Absent 247 (82.33%) |
| Present 100                   | 45 (45.00%)             | 55 (55.00%)             |
| Absent 200                    | 8 (4.00%)               | 192 (96.00%)            |
| Loss of vision                | FNP absent ptosis absent| FNP absent ptosis present|
| Present                       | 28                      | 27                      |
| Absent                        | 174                     | 18                      |
of vision or visual disturbances were observed in 33.3% of the cases when compared with 65% reported by Yohai et al. [8] and 25% by Ferry et al. [9].

Significant neurological findings observed in our study was mainly LMN type facial nerve palsy with signs of drooping of the corner of the mouth, drooling of saliva and absence of wrinkles in the half of the forehead. With regards to symptomatology, our patients had more extensive involvement than reported by Yohai et al. [8] particularly with regard to facial swelling (84.3% vs. 30%), nasal ulceration or necrosis (76% vs. 48%) as seen on DNE, jaw pain or palatal necrosis (18.67% vs. 32%), and LMN facial palsy (17.67% vs. 22%). 51 patients had both ptosis and FNP, 45% had loss of vision with FNP and 45 of them had ptosis, FNP and loss of vision.

Involvement of cranial nerves albeit not common, facial nerve palsy is a rare finding. ROCM can mimic cerebrovascular accidents due to involvement of multiple cranial nerves. Cranial nerve findings imply a much more severe infection and signal a grave prognosis. The previous reported literature showed frequency of unilateral LMN FNP in conjunction with ROCM to be 11% [10] however in our study, it was bit higher, we had 53 (17.7%) patients who presented with FNP with right side being more involved than the left.

The exact mechanism of involvement of the facial nerve in mucormycosis is unknown, and no definite pathology of the facial nerve has been identified. Recent studies have demonstrated spread of mucorales species along the peripheral nerves [11]. Some authors consider pterygopalatine fossa as a reservoir for the and route of spread of mucormycosis to the facial nerve [11]. The pathway of spread to involve the facial nerve is believed to start from the nasal mucosa, spreading to the maxillary, ethmoid sinuses, orbit, pterygopalatine fossa finally to the infra temporal fossa and then extending intracranially [10].

So, the infection reaching the pterygopalatine fossa can spread to the inferior orbital fissure, orbital apex, and infra temporal fossa. The juxtaposition of the greater superficial petrosal nerve. An isolated involvement of the intracanalicular facial nerve within the temporal bone can occur along the nerve sheath of this nerve [12, 13]. Facial nerve may also be affected by direct spread through the Eustachian tube or through the vascular channels into middle ear. Another reason of involvement of facial nerve palsy can be the pathology of resistance arteries in diabetic patients which may cause oedema and localize facial nerve ischemia. This would compromise the blood supply to the nerve leading to palsy. Facial nerve palsy can also be incidental and may be idiopathic as in Bell’s palsy.

### Table 3: Distribution of various sites of involvement radiologically among 300 patients of CAM

| Site of Involvement          | RIGHT (n = 300) | LEFT (n = 300) |
|------------------------------|----------------|---------------|
| Maxillary sinus              | 205 (68.3%)    | 174 (58%)     |
| Ethmoid sinus                | 146 (48.6%)    | 119 (39.6%)   |
| Sphenoid sinus               | 93 (31%)       | 74 (24.6%)    |
| Frontal sinus                | 106 (35.3%)    | 89 (29.6%)    |
| Premaxillary area            | 171 (57%)      | 148 (49.3%)   |
| Retromaxillary area          | 130 (43.3%)    | 96 (32%)      |
| Middle turbinate             | 151 (50.3%)    | 126 (42%)     |
| Inferior turbinate           | 124 (41.3%)    | 104 (34.6%)   |
| Superior turbinate           | 12 (4%)        | 7 (2.3%)      |
| Orbit                        | 151 (50.3%)    | 142 (47.3%)   |
| Orbital apex                 | 13 (4.3%)      | 19 (6.3%)     |
| Cavernous sinus              | 16 (5.3%)      | 12 (4%)       |

### Table 4: Showing association between Diabetes and Facial nerve palsy, Mucormycosis and Facial nerve palsy

| Variant                      | Facial nerve palsy (FNP) |   |   |   |
|------------------------------|--------------------------|---|---|---|
|                             | FNP present (n = 53)     | FNP absent (n = 247) | Total |
| Diabetes Mellitus            |                          |               |       |
| Denovo DM                    | 23/53                    | 129/247       | 152/300 |
| Chronic DM                   | 29/53                    | 104/247       | 133/300 |
| Absent                       | 01/53                    | 14/247        | 15/300  |
| Mucormycosis                 |                          |               |       |
| Present                      | FNP present (n = 53)     | FNP absent (n = 247) |       |
|                             | 53                       | 209           |       |
| Absent                       | 0                        | 38            |       |
| Diabetes Mellitus            |                          |               |       |
| FNP present HPE positive     | 0                        | 109           | 20     |
| FNP present HPE negative     | 0                        | 86            | 18     |
| FNP absent HPE positive      | 1                        | 14            | 0      |
| FNP absent HPE negative      |                          |               |       |
| Denovo DM                    | 23/53                    | 0             | 109    |
| Chronic DM                   | 29/53                    | 0             | 86     |
| Absent                       | 1                        | 0             | 14     |

 Springer
In our study out of the 300 patients suspected of CAM the most common epidemiologica1 factor was diabetes mellitus. Majority 285 (95%) patients were either newly diagnosed 152 (50.67%) or pre-existing diabetics 133(44.33%). 52 patients who developed FNP in our study were all diabetics with CAM. All the 53 patients with FNP had mucormycosis. Previous studies in literature have shown involvement of the facial nerve due to vascular ischaemia caused by microthromi among Covid 19 positive patients[14, 15]. Various studies have also mentioned involvement of the facial nerve among diabetic patients. [16–18]

According to our study, the involvement of facial nerve could be mainly due to the extent and rapid spread of the disease, past Covid 19 Status and diabetes would be contributory. However there is also a possibility that it also could be coincidental and we need to collect more data that reflects FNP positive without mucormycosis among COVID 19 positive patients.

Computed tomography or magnetic resonance imaging are useful modalities to assess the extent of the disease. Bone erosion is not a typical finding seen in ROCM, as the fungus is highly angioinvasive which leads to extensive necrosis of tissues, and thus CT scan may fail in detecting early disease. In our series, contrast enhanced MRI of the paranasal sinuses, orbit and brain was the preferred imaging modality of choice. It detects early involvement of soft tissues especially in cases with extensive orbital and intracranial spread. On MRI, Facial nerve involvement may be diagnosed by widening of pterygopalatine fossa,. Perineural invasion has been documented using contrast enhanced MRI [19].

In our study paranasal sinuses were involved in all patients, with ethmoid (right—48.6% and left—39.6) and maxillary (right—68% and left—58%) being the most frequent, while Ferry and Yohai reported sinuses involvement in 69% and 79% respectively. cavernous sinus thrombosis usually results from spread of infection from the orbit and appears as a filling defect within the enhancing sinus or as a lateral convexity, and was evident in 5.3% on right side and 4% on the left side.

Diagnostic nasal endoscopy allows for quick inspection to look for a black eschar and thus allowing to take biopsy for microbiological and HPE. Diagnosis is confirmed histologically by detection of aseptate hyphae with right angled branching which is pathognomonic of mucormycosis. The impact of facial nerve palsy on the overall prognosis of patients with mucormycosis is yet to be determined and cannot be derived from our case series.

The management of mucormycosis essentially involves control of hyperglycemia or any other risk factor, optimal surgical debridement, and medical management with antifungal agents. Previous published literature showed that survival was 70% when treated with both amphotericin and surgical debridement, 61% with amphotericin deoxycholate, 57% with surgery alone and only 3% in patients who underwent no treatment [20].

Amphotericin B is the antifungal drug of choice for mucormycosis. It has been used in 88% of the patients of CAM. Even in our series, almost all patients had received liposomal amphotericin B. The liposomal form is preferred since it is less nephrotoxic and, therefore, higher doses may be given for a prolonged duration. In patients with compromised renal functions, posaconazole and isavuconazole have been found to be effective alternatives. Endoscopic surgical debridement of paranasal sinuses was performed as a primary management in all of the cases in our series. Simultaneous PNS debridement with orbital exenteration or intraorbital amphotericin injection or maxillectomy was performed in cases based on the extent of disease. Orbital exenteration is conventionally done in cases with no visual potential, with diffuse orbital involvement, but with the disease limited to the orbit without or minimal extension to the cavernous sinus. CAM is a rapidly progressive disease, with a high 30—90% mortality rate in cases with intracranial involvement. For cases associated with Covid-19, the overall mortality has been estimated to be 31%.

Conclusion

CAM predominantly affects middle aged males and DM is the most common epidemiological factor for CAM. Good glycemic control is of paramount importance in a patients with Covid-19 in preventing rapid progression of the disease. The red flag signs and symptoms of severe headache, facial pain, eye pain, jaw pain and visual disturbances should be recognized promptly, followed by a confirmatory diagnosis by diagnostic nasal endoscopy and HPE. Contrast-enhanced MRI is the imaging modality of choice. Liposomal amphotericin B is the drug of choice for treatment of CAM. PNS debridement should be radical and may be combined with orbital exenteration/maxillectomy based on the extent of disease. To highlight involvement of facial nerve paresis as a presenting feature in rhino cerebral mucormycosis. A meticulous history, detailed workup, confirmation of diagnosis by histopathology and culture helps to make diagnosis. Aggressive management of these patients can reverse the adverse outcome. Prognosis of CAM is directly dependant on multiple factors and early initiation of treatment is an important element.

Acknowledgements The authors would like to gratefully acknowledge the medical postgraduates and consultants who contributed in collection of data for this article. We are also grateful to all the patients who volunteered to participate in this study. The authors would like to gratefully acknowledge and thank the medical supernintedent and faculty for accepting for publication.

 Springer
References

1. Ammari L, Kilani B, Tiouiri H, Kanoun F, Goubontini A, Mnif E, Zuotien F, Chaker E, Ben Chaabane T (2008) Mucormycosis: four case reports. Tunis Med 86(2):165–168
2. Hirabayashi KE, Idowu OO, Kalin-Hajdu E, Oldenburg CE, Brodie FL, Kersten RC, Vagefi MR (2019) Invasive fungal sinusitis: risk factors for visual acuity outcomes and mortality. Ophthalmic plast reconstr surg 35(6):535–542. https://doi.org/10.1097/IOP.0000000000001357
3. Davis RL, Robertson DM (1985) Textbook of neuropathology. Williams & Wilkins
4. Smith HW, Kirchner JA (1958) Cerebral mucormycosis; a report of three cases. A M A. Arch otolaryngol 68(6):715–726. https://doi.org/10.1001/archotol.1958.00730020739010
5. Song YM, Shin SY (2008) Bilateral ophthalmic artery occlusion in rhino-orbito-cerebral mucormycosis. Korean J Ophthalmol KJO 22(1):66–69. https://doi.org/10.3341/kjo.2008.22.1.66
6. Singh NP, Garg S, Kumar S, Gulati S (2006) Multiple cranial nerve palsies associated with type 2 diabetes mellitus. Singap Med J 47(8):712–715
7. Koc Z, Koc F, Yerdenel D, Oxdogu H (2007) Rhino-orbital-cerebral mucormycosis with different cerebral involvements: infarct, hemorrhage, and ophthalmoplegia. Int J Neurosci 117(12):1677–1690. https://doi.org/10.1080/00220460601050238
8. Yohai RA, Ballock JD, Aziz AA, Markert RJ (1994) Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39(1):3–22. https://doi.org/10.1016/s0161-6423(83)80052-9
9. Ferry AP, Abedi S (1983) Diagnosis and management of rhino-orbitocerebral mucormycosis phlycomycosis. A report of 16 personally observed cases. Ophthalmology 90(9):1096–1104. https://doi.org/10.1016/s0161-6423(83)80052-9
10. Ferguson BJ (2000) Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 33(2):349–365. https://doi.org/10.1016/s0030-6665(00)80010-9
11. Hosseini SM, Borgheri P (2005) Rhinocerebral mucormycosis: pathways of spread. European archives of oto-rhino-laryngology